Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas

Cancer

Volumn 119, Issue 15, 2013, Pages 2765-2770

  Sinicrope, Frank A ^a,b   Smyrk, Thomas C ^b   Tougeron, David ^b   Thibodeau, Stephen N ^b   Singh, Shalini ^c   Muranyi, Andrea ^c   Shanmugam, Kandavel ^c   Grogan, Thomas M ^c   Alberts, Steven R ^a,b   Shi, Qian ^b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

BRAFV600E mutation; BRAFV600E protein; colon cancer; immunohistochemistry; microsatellite instability

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID; MUTANT PROTEIN; OXALIPLATIN; PROTEIN ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; ONCOGENE B RAF; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCORING SYSTEM; STAINING; TUMOR CELL;

BRAFV600E MUTATION; BRAFV600E PROTEIN; COLON CANCER; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY;

AGED; ANTIBODIES; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; POINT MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84880572740     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28133     Document Type: Article

References (27)

1. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012; 18: 890-900.
2. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
3. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012; 18: 6531-6541.
4. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998; 338: 1481-1487.
5. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38: 787-793.
6. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE,. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418: 934-934.
7. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004; 41: 664-668.
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
9. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-365.
10. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009; 101: 465-472.
11. Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer. 2010; 102: 1762-1768.
12. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-2019.
13. Sinicrope FA, Mahoney MR, Smyrk TC,. Prognostic impact of DNA mismatch repair status and BRAFV600E mutations in stage III colon cancer patients treated in a phase III study of adjuvant FOLFOX alone or combined with cetuximab: NCCTG N0147. Ann Oncol. 2012; 23: 17-18.
14. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466-474.
15. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
16. Arcila M, Lau C, Nafa K, Ladanyi M,. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011; 13: 64-73.
17. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012; 307: 1383-1393.
18. Sinicrope FA, Rego RL, Garrity-Park MM, et al. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer. 2007; 120: 1232-1238.
19. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011; 122: 11-19.
20. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012; 123: 223-233.
21. Feller JK, Yang S, Mahalingam M,. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol. 2013; 26: 414-420.
22. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol. 2013; 24: 742-748.
23. Wilmott JS, Menzies AM, Haydu LE, et al. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer. 2013; 108: 924-931.
24. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013; 37: 61-65.
25. Borras E, Jurado I, Hernan I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing [serial online]. BMC Cancer. 2011; 11: 406.
26. Heideman DA, Lurkin I, Doeleman M, et al. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of 3 testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn. 2012; 14: 247-255.
27. Kastrinos F, Syngal S,. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? J Clin Oncol. 2012; 30: 1024-1027.